SEC Form 8-K Summary
Registrant: Galecto, Inc. (metadata identifies Damora Therapeutics, Inc.; the filing itself names Galecto, Inc.)
Reporting date: January 8, 2021. The filing reports a board appointment under Item 5.02 and furnishes a related press release under Item 9.01.
Business Context and Reporting Period
Galecto, Inc. is a Delaware corporation headquartered in Copenhagen, Denmark, with common stock traded on the Nasdaq Global Select Market under the symbol GLTO. The company reported the appointment of Anne Prener to its board of directors, effective January 8, 2021.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics.
Material Changes
- The board increased its size to nine directors.
- Anne Prener was appointed as a Class I director. Her initial term expires at the 2021 annual meeting, where she is expected to stand for election by stockholders.
- The board determined that Dr. Prener is independent under Nasdaq listing standards.
- As a non-employee director, Dr. Prener will receive cash compensation and equity awards under the company’s amended Non-Employee Director Compensation Policy, including an initial grant and a pro rata portion of an annual grant.
- Dr. Prener entered into an indemnification agreement consistent with those executed with the company’s existing non-employee directors.
Management Commentary, Risks, and Unusual Items
The filing states that Dr. Prener is not party to any transaction requiring disclosure under Item 404(a) of Regulation S-K. It also states that no arrangements or understandings existed between Dr. Prener and other persons regarding her selection as a director. The filing does not identify new business risks, contingencies, or unusual financial items.
Investor Verification Items
- Verify the registrant’s identity, because the supplied metadata names Damora Therapeutics, Inc., while the filing names Galecto, Inc.
- Review Exhibit 99.1 for the company’s announcement and additional background regarding Dr. Prener.
- Review subsequent filings for the terms and valuation of Dr. Prener’s equity awards and any changes following the 2021 annual meeting.
- Consult the company’s next periodic report for financial condition, liquidity, operating results, and updated outlook, none of which are provided in this 8-K.